LEADING CAUSES OF U.S. DEATHS

Medical misdiagnosis ranked 3rd by Johns Hopkins investigators⁴

250,000

edical solidanosis

4.) www.ncbi.nlm.nih.gov/pubmed/27143499





THE PRICE WE PAY

U.S. Stroke Estimates, 11 years from now.³

Estimates to be 3.4 million

Cases

\$34p

\$240 billion

3.) www.ncbi.nlm.nih.gov/pubmed/23697546

ACCIPIO®

MaxQ AI will support the complete Accipio ICH and Stroke Platform with INSIGHT™:

It will support the Radiology Department, Emergency Room, Neuroradiology, and the Stroke teams with a fully-automated solution. The Accipio platform will provide tools for identification & prioritization (lx)¹, slice-level annotation (Ax)², and triage guidance or suspected ICH presence and diagnostic quality rule-out. The complete Accipio solution for head trauma and stroke promises to:

- Greatly increase ICH detection and reduce missed ICHs through near real-time triage, annotation, and diagnostic rule-out because every minute matters for TBI, trauma, and stroke patients
- Potentially enhance clinical confidence, including mobilization of ischemic stroke and neurosurgery teams
- Provide the right care readied faster, improving quality to potentially avoid poor patient outcomes and to decrease costs and liability
- Provide slice-level annotation, lesion-level annotation, and quantification of lesion volume within suspected ICH
- Provide automatic diagnostic ICH rule-out

Accipio Future Device Accipio Ix Accipio Ix Suspected acute CH found Diagnostic Rule Out

Identification & Prioritization

1.) Accipio Ix: FDA Cleared and CE Approved 2.) Accipio Ax: FDA Cleared and CE Approved





INTEGRATED, SEAMLESS, TRUSTED.

Deployed globally through Major CT, AI ecosystem, and PACS channel partners; completely integrated, supported, and serviced from companies you trust.

MaxQ Al PARTNERS

- GE Healthcare
- IBM Watson Health
- Philips
- TeraRecon
- Blackford
- Arterys
- Nuance
- Samsung NeuroLogica
- Intel

OUR MISSION

We are reinventing patient diagnosis by making Al intrinsic to the diagnostic process and driving significant reductions in misdiagnosis and healthcare costs.

We enable doctors to make faster, more accurate decisions, particularly in diagnosing time sensitive and lifethreatening conditions.





MaxQ AI AT THE FOREFRONT OF HEALTHCARE AI

- MaxQ Al is reinventing the medical diagnostic paradigm, making Al intrinsic to the process, leading to greater diagnostic speed & accuracy and lower cost
- Focused on critical bedside decisions with direct clinical and economic impact, reducing misdiagnosis and costs
- Global commercial distribution reach through existing and pending channel agreements with some of the largest CT and PAC vendors and cloud providers
- World class deep learning & vision experts that have developed an AI based platform to enable rapid development and scale
- Our first solution, Accipio, revolutionizes brain bleed/ICH triage, detection and rule-out with FDA Breakthrough status, clearances and CE approvals



